Diversify Wealth Management LLC Has $2.13 Million Position in Novo Nordisk A/S (NYSE:NVO)

Diversify Wealth Management LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 31.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,693 shares of the company’s stock after selling 11,099 shares during the period. Diversify Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,130,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S during the third quarter worth $98,765,000. Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $42,017,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 5.2 %

NYSE NVO opened at $78.74 on Tuesday. The stock’s 50 day moving average price is $97.76 and its two-hundred day moving average price is $116.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15.

Analysts Set New Price Targets

NVO has been the subject of a number of recent research reports. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.